Health
Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection – News-Medical.Net
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental…
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.
Separate phase 2 and 3 clinical trials are ongoing to evaluate EIDD-2801 safety in humans and its effect on viral shedding in COVID-19 patients.
The number of new COVID-19 cases continues to…
-
Business24 hours agoThese top ASX 200 stocks could rise 25% to 60%
-
Noosa News24 hours agoDid AI write your accounting expert’s report? – Proctor
-
Noosa News24 hours agoMin Woo Lee, Adam Scott and Cameron Smith in the mix after Australian PGA opening round in Brisbane
-
General23 hours agoWith a deal on Australia’s environmental laws, Murray Watt has cemented his reputation as a ‘fixer’